Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Embolic versus thrombotic occlusion

Essential points for quick revision.

Saved on this device
!
Cause follows viability

Both embolic and thrombotic occlusion can produce an immediately threatened limb; aetiological uncertainty must not slow reperfusion.

Action: Assess sensory and motor function, contact vascular surgery immediately, give intravenous unfractionated heparin unless contraindicated, and let the vascular team select imaging that does not delay a threatened limb.

Synopsis

Differentiate likely embolic from in-situ thrombotic acute limb occlusion while preserving identical emergency assessment and limb-salvage priorities.

  • Sudden maximal symptoms, a normal opposite limb, absent prior claudication and atrial fibrillation favour embolism; previous claudication, diffuse pulse loss and bilateral PAD favour thrombosis in situ.
  • Do not let cause-finding delay limb rescue: map sensory loss and weakness, contact vascular surgery immediately, and give intravenous unfractionated heparin unless active bleeding or current or previous HIT contraindicates it.
  • Neurological deficit requires emergency revascularisation and imaging only when it will not delay treatment; profound anaesthesia, paralysis and absent arterial plus venous signals suggest Rutherford III.

Key red flags

Any new motor weakness or sensory loss beyond the toes means immediate limb threat irrespective of whether embolism or thrombosis is more likely.

Profound anaesthesia, paralysis or rigor with absent arterial and venous Doppler signals suggests irreversible tissue injury and major reperfusion hazard.

Chest or back pain, pulse asymmetry or haemodynamic instability raises aortic dissection or proximal aortic occlusion rather than an isolated leg lesion.

Massive swollen cyanotic limb with preserved arterial inflow can indicate phlegmasia and also requires emergency vascular assessment.

Active major bleeding or known immune HIT changes initial anticoagulation choice, but the vascular referral remains immediate.

Tempo of onset

Instantaneous, maximal-at-onset pain and dysfunction favour embolism, whereas thrombosis may worsen over hours on a background of chronic symptoms, although either mechanism can present abruptly.

Threat overrides mechanism

Sensory loss beyond the toes or any motor weakness identifies an immediately threatened limb requiring emergency revascularisation regardless of aetiological confidence.

Investigation priorities

01
CT angiographyFirst step

Define occlusion morphology, background arterial disease, inflow and distal runoff.

Management branches

Initial mechanism assessmentSeparate probability from emergency action

A patient presents with acute painful cold limb and the cause is uncertain.

  1. Grade Rutherford viability from symptom duration, sensory loss, motor power and Doppler signals while contacting the vascular service immediately.
  2. Give analgesia and intravenous unfractionated heparin unless contraindicated; arrange emergency treatment without waiting to prove embolism or thrombosis.

Key medicines

Unfractionated heparinThe licensed UK regimen for acute peripheral arterial occlusion is 5,000 IU intravenously followed by 1,000–2,000 IU/hour continuous intravenous infusion, with APTT sampled 4–6 hours after initiation and dose adjusted.Withhold in active major haemorrhage and avoid with current or previous immune heparin-induced thrombocytopenia; urgently balance other bleeding sites and recent brain, spinal or eye surgery. Check baseline platelets and coagulation, then use the hospital UFH nomogram for preparation and assay-specific targets.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 12 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 12 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom